Table 2.

Objective response rates to vorinostat

Patient populationsAll patients as treated
Per-protocol analysis
nResponders, n (%)95% CInResponders, n (%)95% CI
All patients7422 (30)19.7-41.56521 (32)21.2-45.1
Stage IIB or higher6118 (30)18.5-42.65417 (32)19.5-45.6
Patients with S├ęzary syndrome3010 (33)17.3-52.8279 (33)16.5-54.0
Patients with T3 tumor disease225 (23)7.8-45.4205 (25)8.7-49.1